(Reuters) - Generic drugmaker Mylan NV beat Wall Street estimates for third-quarter profit on Tuesday, benefiting from drug launches such as Wixela and Fulphila, sending its shares up 2% before the opening bell.Mylan in July agreed to merge with Pfizer Inc's Upjohn unit that houses off-patent branded drugs, forming one of the largest companies selling low-cost prescription medicines.The deal will allow Mylan to leverage a strong base in Asia through Upjohn, headquartered in China, a prime..